Your browser doesn't support javascript.
loading
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.
Scalera, S; Ricciuti, B; Mazzotta, M; Calonaci, N; Alessi, J V; Cipriani, L; Bon, G; Messina, B; Lamberti, G; Di Federico, A; Pecci, F; Milite, S; Krasniqi, E; Barba, M; Vici, P; Vecchione, A; De Nicola, F; Ciuffreda, L; Goeman, F; Fanciulli, M; Buglioni, S; Pescarmona, E; Sharma, B; Felt, K D; Lindsay, J; Rodig, S J; De Maria, R; Caravagna, G; Cappuzzo, F; Ciliberto, G; Awad, M M; Maugeri-Saccà, M.
Afiliação
  • Scalera S; SAFU Laboratory, Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Ricciuti B; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
  • Mazzotta M; Medical Oncology Unit, Sandro Pertini Hospital, Rome, Italy.
  • Calonaci N; Department of Mathematics and Geosciences, University of Trieste, Trieste, Italy.
  • Alessi JV; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
  • Cipriani L; SAFU Laboratory, Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Bon G; Cellular Network and Molecular Therapeutic Target Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Messina B; Clinical Trial Center, Biostatistics and Bioinformatics Division, IRCCS Regina Elena National Cancer Institute, Roma, Italy.
  • Lamberti G; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
  • Di Federico A; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
  • Pecci F; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
  • Milite S; Department of Mathematics and Geosciences, University of Trieste, Trieste, Italy.
  • Krasniqi E; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Barba M; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Vici P; UOSD Phase IV Studies, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Vecchione A; Department of Clinical and Molecular Medicine, Pathology Unit, Sant'Andrea Hospital, Sapienza University, Rome, Italy.
  • De Nicola F; SAFU Laboratory, Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Ciuffreda L; SAFU Laboratory, Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Goeman F; SAFU Laboratory, Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Fanciulli M; SAFU Laboratory, Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Buglioni S; Department of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Pescarmona E; Department of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Sharma B; ImmunoProfile, Brigham & Women's Hospital and Dana-Farber Cancer Institute, Boston, USA.
  • Felt KD; ImmunoProfile, Brigham & Women's Hospital and Dana-Farber Cancer Institute, Boston, USA.
  • Lindsay J; Knowledge Systems Group, Dana-Farber Cancer Institute, Boston, USA.
  • Rodig SJ; ImmunoProfile, Brigham & Women's Hospital and Dana-Farber Cancer Institute, Boston, USA; Department of Pathology, Brigham and Women's Hospital, Boston, USA.
  • De Maria R; Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Caravagna G; Department of Mathematics and Geosciences, University of Trieste, Trieste, Italy.
  • Cappuzzo F; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Ciliberto G; Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Awad MM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
  • Maugeri-Saccà M; Clinical Trial Center, Biostatistics and Bioinformatics Division, IRCCS Regina Elena National Cancer Institute, Roma, Italy; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy. Electronic address: marcello.maugerisacca@ifo.it.
Ann Oncol ; 34(3): 275-288, 2023 03.
Article em En | MEDLINE | ID: mdl-36526124
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma de Pulmão / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma de Pulmão / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália